Invitrogen Launches Countess™

  
    
  
  
    
      Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life 
      science technologies for research, production and diagnostics, today 
      announced the introduction of a new benchtop instrument, Countess™ 
      automated cell counter, which offers a new method of automated cell 
      counting to replace manual cell counting using a glass hemocytometer.
    
    
      “This instrument was designed with the 
      scientists’ workflows in mind, and adds to 
      Invitrogen’s already productive line of 
      benchtop instruments, as well as the full line of reagents to support 
      those instruments,” said August Sick, General 
      Manager and Vice President of Invitrogen’s 
      Cellular Analysis Business Unit. “The Countess 
      automates a very tedious and subjective manual process and gives 
      accurate, repeatable results, freeing scientists to concentrate their 
      efforts on the outcomes rather than the process.”
    
    
      Currently, researchers use a glass slide with a grid pattern, count 
      cells one by one, add the number of cells in each box and multiply that 
      number by a dilution factor to calculate the final concentration of 
      cells. The Countess automates this process, completing all counts and 
      calculations in approximately 30 seconds.
    
    
      The Countess™ instrument:
    
    
      
        Counts live and dead cells
      
      
        Calculates percent viability
      
      
        Measures average cell size
      
      
        Calculates dilutions for downstream applications
      
      
        Uses just 10 microliters of sample
      
    
    
      For more information about the instrument and related reagents visit www.invitrogen.com/countess.
    
    
      Invitrogen also currently offers the Qubit™ 
      Quantitation System, for the quantitation of DNA, RNA and protein 
      samples, the iPrep™ 
      Purification Instrument for the purification of DNA and RNA, and the iBlot® 
      for the transfer of proteins in the Western Blotting process.
    
    
      Invitrogen Corporation was also recently cited by The Patent Board as 
      the second leading company for science strength in its Patent 
      Scorecard for Biotechnology.
    
    
      About Invitrogen
    
    
      Invitrogen Corporation (NASDAQ:IVGN) provides products and services that 
      support academic and government research institutions and pharmaceutical 
      and biotech companies worldwide in their efforts to improve the human 
      condition. The company provides essential life science technologies for 
      disease research, drug discovery, and commercial bioproduction. 
      Invitrogen’s own research and development 
      efforts are focused on breakthrough innovation in all major areas of 
      biological discovery including functional genomics, proteomics, stem 
      cells, cell therapy and cell biology -- placing Invitrogen’s 
      products in nearly every major laboratory in the world. Founded in 1987, 
      Invitrogen is headquartered in Carlsbad, California, and conducts 
      business in more than 70 countries around the world. The company employs 
      approximately 4,700 scientists and other professionals and had revenues 
      of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.